Literature DB >> 33441091

Evaluation of undetected cases during the COVID-19 epidemic in Austria.

C Rippinger1,2, M Bicher3,4, C Urach3, D Brunmeir3, N Weibrecht3, G Zauner3, G Sroczynski5, B Jahn5,6, N Mühlberger5, U Siebert5,6,7,8, N Popper3,4.   

Abstract

BACKGROUND: Knowing the number of undetected cases of COVID-19 is important for a better understanding of the spread of the disease. This study analyses the temporal dynamic of detected vs. undetected cases to provide guidance for the interpretation of prevalence studies performed with PCR or antibody tests to estimate the detection rate.
METHODS: We used an agent-based model to evaluate assumptions on the detection probability ranging from 0.1 to 0.9. For each general detection probability, we derived age-dependent detection probabilities and calibrated the model to reproduce the epidemic wave of COVID-19 in Austria from March 2020 to June 2020. We categorized infected individuals into presymptomatic, symptomatic unconfirmed, confirmed and never detected to observe the simulated dynamic of the detected and undetected cases.
RESULTS: The calculation of the age-dependent detection probability ruled values lower than 0.4 as most likely. Furthermore, the proportion of undetected cases depends strongly on the dynamic of the epidemic wave: during the initial upswing, the undetected cases account for a major part of all infected individuals, whereas their share decreases around the peak of the confirmed cases.
CONCLUSIONS: The results of prevalence studies performed to determine the detection rate of COVID-19 patients should always be interpreted with regard to the current dynamic of the epidemic wave. Applying the method proposed in our analysis, the prevalence study performed in Austria in April 2020 could indicate a detection rate of 0.13, instead of the prevalent ratio of 0.29 between detected and estimated undetected cases at that time.

Entities:  

Keywords:  Agent-based modelling; COVID-19; Undetected cases

Year:  2021        PMID: 33441091     DOI: 10.1186/s12879-020-05737-6

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  5 in total

1.  Identification of the first COVID-19 infections in the US using a retrospective analysis (REMEDID).

Authors:  David García-García; Enrique Morales; Cesar de la Fuente-Nunez; Isabel Vigo; Eva S Fonfría; Cesar Bordehore
Journal:  Spat Spatiotemporal Epidemiol       Date:  2022-05-10

2.  Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities-An Agent-Based Modeling Evaluation.

Authors:  Beate Jahn; Gaby Sroczynski; Martin Bicher; Claire Rippinger; Nikolai Mühlberger; Júlia Santamaria; Christoph Urach; Michael Schomaker; Igor Stojkov; Daniela Schmid; Günter Weiss; Ursula Wiedermann; Monika Redlberger-Fritz; Christiane Druml; Mirjam Kretzschmar; Maria Paulke-Korinek; Herwig Ostermann; Caroline Czasch; Gottfried Endel; Wolfgang Bock; Nikolas Popper; Uwe Siebert
Journal:  Vaccines (Basel)       Date:  2021-04-27

3.  Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.

Authors:  Martin Bicher; Claire Rippinger; Günter Schneckenreither; Nadine Weibrecht; Christoph Urach; Melanie Zechmeister; Dominik Brunmeir; Wolfgang Huf; Niki Popper
Journal:  Sci Rep       Date:  2022-02-21       Impact factor: 4.379

4.  How an election can be safely planned and conducted during a pandemic: Decision support based on a discrete event model.

Authors:  Nadine Weibrecht; Matthias Rößler; Martin Bicher; Štefan Emrich; Günther Zauner; Niki Popper
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

5.  An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply.

Authors:  Martin Bicher; Claire Rippinger; Melanie Zechmeister; Beate Jahn; Gaby Sroczynski; Nikolai Mühlberger; Julia Santamaria-Navarro; Christoph Urach; Dominik Brunmeir; Uwe Siebert; Niki Popper
Journal:  PLoS One       Date:  2022-05-02       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.